TechnipFMC Free cash flow decreased by 22.9% to $276.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 27.1%, from $379.90M to $276.90M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 25.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$125.60M | $88.60M | $423.00M | -$356.70M | -$133.00M | $181.10M | $502.80M | -$443.50M | $103.40M | $178.30M | $629.60M | -$178.70M | $180.10M | $225.30M | $452.70M | $379.90M | $260.60M | $447.80M | $359.10M | $276.90M |
| QoQ Change | — | +170.5% | +377.4% | -184.3% | +62.7% | +236.2% | +177.6% | -188.2% | +123.3% | +72.4% | +253.1% | -128.4% | +200.8% | +25.1% | +100.9% | -16.1% | -31.4% | +71.8% | -19.8% | -22.9% |
| YoY Change | — | — | — | — | -5.9% | +104.4% | +18.9% | -24.3% | +177.7% | -1.5% | +25.2% | +59.7% | +74.2% | +26.4% | -28.1% | +312.6% | +44.7% | +98.8% | -20.7% | -27.1% |